The Chinese biopharmaceutical contract manufacturing market is estimated to be worth USD 2.6 billion in 2030, predicts Roots Analysis
The growing biopharma
industry in China has resulted in the creation of lucrative business
opportunities for contract service providers; region-specific advantages have
also attracted several foreign sponsors entities over the last few years
Roots Analysis is pleased to announce the publication of its recent
study, titled, “China
Biopharmaceutical Contract Manufacturing Market, 2020-2030.”
The report features
an extensive study of the current market landscape and future opportunities
associated with the contract manufacturing of biopharmaceuticals in China. The
study also features a detailed analysis of key drivers and trends related to
this evolving domain. In addition to other elements, the study includes:
§
A detailed assessment of the current market landscape of companies
offering contract manufacturing services for biopharmaceuticals in China.
§
An analysis of the partnerships that have been established
in this domain, in the recent past.
§
An analysis of the expansion initiatives undertaken by
contract manufacturers in China, in order to augment their capabilities, in the
recent past.
§
A detailed analysis of more than 1500 clinical trials related
to biopharmaceuticals that have been / are being / are likely to be conducted
in China.
§
An estimate of the overall, installed capacity for
manufacturing biopharmaceuticals, based on data reported by industry
stakeholders in the public domain.
§
An analysis of the initiatives of big biopharma players
engaged in this domain.
§
A qualitative analysis, highlighting the various factors
that need to be taken into consideration by drug / therapy developers while
deciding whether to manufacture their respective products in-house or engage
the services of a CMO.
§
Detailed profiles of key players that have a diverse range
of capabilities for the development, manufacturing, and packaging of biopharmaceutical
products.
§
A case study comparing the key characteristics of large
molecule and small molecule drugs.
§
A discussion on industry affiliated trends, key drivers,
and challenges, under a SWOT framework, which are likely to impact the
evolution of this field.
§
A detailed market forecast, featuring analysis of the
current and projected future opportunity across key market segments (listed
below)
- Type of Product
§
API
§
FDF
- Type of Expression System Used
§
Mammalian
§
Microbial
§
Others
- Scale of Operation
§
Preclinical / Clinical
§
Commercial
- Size of Manufacturer
§
Small
§
Mid-sized
§
Large / Very Large
- Type of Biologic
§
Antibody
§
Vaccine
§
Others
§
ChemPartner Biologics
§
JHL Biotech
§
JOINN Biologics
§
MabPlex
§
Mycenax Biotech
§
WuXi AppTec
For more information please click on the following link:
Other Recent
Offerings
About Roots Analysis
Roots Analysis is one
of the fastest growing market research companies, sharing fresh and independent
perspectives in the bio-pharmaceutical industry. The in-depth research,
analysis and insights are driven by an experienced leadership team which has
gained many years of significant experience in this sector. If you’d like help
with your growing business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots Analysis
Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
gaurav.chaudhary@rootsanalysis.com
Comments
Post a Comment